Feature BeyondSpring readies NDA filings for Plinabulin in U.S. and China BeyondSpring (NASDAQ:BYSI) is preparing to file NDAs with the China FDA during the next six months for its lead asset, first-in-class agent Plinabulin, for the treatment of non-small cell lung cancer (NSCLC) and... January 8, 2019